Date published: 2025-10-11

1-800-457-3801

SCBT Portrait Logo
Seach Input

A830080D01Rik Inhibitors

Chemical inhibitors of Bclaf1 and Thrap3 include a range of compounds that target various signaling pathways and cellular processes. Staurosporine serves as a potent protein kinase inhibitor, thereby obstructing the phosphorylation events that are critical for the functional activity of Bclaf1 and Thrap3. By blocking these phosphorylation events, Staurosporine can inhibit the activation and subsequent actions of these proteins. Similarly, Alsterpaullone acts on cyclin-dependent kinases (CDKs), which are integral to cell cycle progression. Given that Bclaf1 and Thrap3 have roles in cell cycle regulation, the inhibition of CDKs by Alsterpaullone can disrupt the cell cycle-related functions of these proteins.

The MEK inhibitors U0126 and PD98059 target the MEK1/2 enzymes, which leads to a suppression of the ERK signaling pathway. The ERK pathway is implicated in regulating transcription factors that may interact with Bclaf1 and Thrap3, and thus, inhibition by U0126 and PD98059 can disrupt these interactions, leading to a functional inhibition of Bclaf1 and Thrap3. LY294002 and Wortmannin inhibit the PI3K/Akt signaling pathway, which is known to participate in a variety of cellular processes including those in which Bclaf1 and Thrap3 are involved. By inhibiting PI3K/Akt signaling, these chemicals can inhibit functions of Bclaf1 and Thrap3 associated with this pathway. SB203580 and SP600125 specifically target p38 MAP kinase and JNK, respectively. These kinases are part of the MAPK signaling pathway, which is known to regulate transcription factors and other proteins that could interact with Bclaf1 and Thrap3, leading to inhibition of their activity. Rapamycin directly inhibits mTOR, which is crucial for cap-dependent translation, and this inhibition can affect the protein synthesis of interacting partners of Bclaf1 and Thrap3, leading to an inhibition of their functions. Lastly, 5-Azacytidine and histone deacetylase inhibitors like Trichostatin A and Apicidin target epigenetic modifiers. By inhibiting DNA methyltransferases and histone deacetylases, these chemicals can alter chromatin structure and gene expression profiles, affecting transcription factors or cofactors that are essential for Bclaf1 and Thrap3 activities, thereby inhibiting their function.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Staurosporine

62996-74-1sc-3510
sc-3510A
sc-3510B
100 µg
1 mg
5 mg
$82.00
$150.00
$388.00
113
(4)

Inhibits protein kinases which could lead to the inhibition of phosphorylation events necessary for Bclaf1 and Thrap3 activity.

Alsterpaullone

237430-03-4sc-202453
sc-202453A
1 mg
5 mg
$67.00
$306.00
2
(1)

Inhibits cyclin-dependent kinases (CDKs) which could alter cell cycle progression and thereby inhibit Bclaf1 and Thrap3 involved in cell cycle regulation.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

Inhibits MEK1/2 leading to suppression of the ERK pathway, which is involved in the regulation of transcription factors that might interact with Bclaf1 and Thrap3.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

Inhibits PI3K, affecting AKT signaling and potentially inhibiting cellular processes where Bclaf1 and Thrap3 are involved.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

Inhibits p38 MAP kinase, potentially inhibiting downstream transcription factors associated with Bclaf1 and Thrap3 functions.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

Inhibits JNK, which may inhibit transcription factors or other proteins that interact with Bclaf1 and Thrap3.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

Inhibits PI3K/Akt pathway, potentially disrupting functions and interactions involving Bclaf1 and Thrap3.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

Inhibits MEK, which in turn could inhibit ERK pathway affecting transcription factors interacting with Bclaf1 and Thrap3.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Inhibits mTOR, which could lead to inhibition of cap-dependent translation, affecting proteins interacting with Bclaf1 and Thrap3.

5-Azacytidine

320-67-2sc-221003
500 mg
$280.00
4
(1)

Inhibits DNA methyltransferases, potentially inhibiting transcription factors or cofactors interacting with Bclaf1 and Thrap3.